sur Galimedix, Inc.
Galimedix Therapeutics to Showcase New Amyloid Beta Modulator at AD/PD 2026
Galimedix Therapeutics, a Phase 2 clinical-stage biotechnology firm, announced its participation in the AD/PD™ 2026 Conference in Copenhagen. They plan to present promising pre-clinical data on a next-generation oral amyloid beta aggregation modulator. This advancement aims at enhancing treatments for neurodegenerative diseases like Alzheimer's.
The focus will be on a new prodrug of GAL-201, which demonstrates significantly improved pharmacokinetics. The findings will be shared through a poster session by Dr. Katrin Riemann and Dr. Hermann Russ.
The AD/PD™ 2026 Conference is a significant platform in the field of neurodegenerative disorders, drawing over 5,500 experts globally. It facilitates discourse on the latest research and treatment breakthroughs in Alzheimer's and Parkinson's diseases.
Galimedix is advancing orally administered molecules targeting misfolded amyloid beta to inhibit toxic aggregates formation in the brain. Phase 2 development in Alzheimer's and associated conditions is underway, with additional studies on GAL-101 eye drops for retinal diseases.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Galimedix, Inc.